NEW YORK, Jan. 11 (GenomeWeb News) - The Center for Inherited Disease Research will use Illumina's Sentrix HumanHap300 BeadChip and Infinium Assay for a pilot study of Type 2 diabetes, the company said today.
According to Illumina, one goal of the research is to evaluate its technology for possible adoption as the standard platform for CIDR's genome-wide association service, which is expected to launch in the spring.
Terms of the alliance call for CIDR to use the Sentrix HumanHap300 BeadChip to query more than 317,000 tagSNPs on a single microarray device. Specifically, CIDR is working with Illumina to genotype more than 2,500 case-control samples provided by the Finland-United States Investigation of NIDDM Genetics Study. Funded by the National Institutes of Health, the goal of the FUSION team is to map and identify genetic variants that predispose individuals to Type 2 diabetes.
Financial terms of the alliance were not disclosed.